On Thursday, Edwards Lifesciences stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 75.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners often have an 80 or higher RS Rating as they launch their largest price moves. See if Edwards Lifesciences stock can continue to show renewed price strength and clear that threshold.
Is Edward Lifesciences Stock A Buy?
Edward Lifesciences stock broke out of a flat base on July 25. It's slightly extended and not currently an ideal time to buy shares, see if the stock goes on to offer and clear an appropriate buy point.
Earnings growth decreased last quarter from 16% to 8%. But revenue gains moved higher, from 6% to 12%.
Edwards Lifesciences stock earns the No. 10 rank among its peers in the Medical-Products industry group. Insulet, TransMedics Group and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
